Introduction
According to the American Academy of Sleep Medicine Task Force, obstructive sleep apnea is the complete interruption of airflow to the airway for at least 10 seconds. If the anatomical obstacle or the functional change leads to complete prevention of the inspiratory flow, the patient experiences oxygen desaturation and microarousals, which is defined as hypopnea.
obesity, and there is also evidence of a hereditary component of OSAS. [4] [5] [6] [7] OSAS has become a concern in clinical practice because of its prevalence and because it is a potential risk factor for neurologic diseases such as cerebrovascular accidents, cardiovascular hypertension, acute myocardial infarction, and congestive heart failure, in addition to obesity and metabolic syndrome. However, it remains underdiagnosed.
1,2,8-10
There are many treatment options for OSAS, including positive airway pressure therapy, oral appliances, and surgery. Oral appliances may be used in patients with mild to moderate OSAS and in those with more severe disease who are unable to tolerate continuous positive airway pressure therapy.
11 Thus, the objective of this article is to review the literature to determine which factors best correlate with treatment success in patients with OSAS treated with a mandibular repositioning appliance (MRA).
Review of Literature
MRAs, originally derived from functional dental appliances, are used during sleep to advance the mandible and thus prevent the collapse of oropharynx tissues and tongue base, thereby reducing events of upper airway obstruction. Because they are simple and portable, do not use electricity, and are relatively low cost, they are considered an alternative to the treatment of OSAS. MRAs present favorable results quickly.
1-13
The clinical diagnosis of OSAS is confirmed by polysomnography (PSG), which assesses the parameters of quality, architecture, and sleep continuity; nasal/oral airflow; qualitative and quantitative measure of respiratory effort; oxyhemoglobin saturation; electrocardiogram; and position of the body during sleep.
1,12,14
The PSG quantifies respiratory events per hour of sleep, and AHI confirms the diagnosis. This index is the number of times the air passage is blocked (apnea) or reduced (hypopnea) over 10 seconds each hour of sleep. An AHI of 5 to 15 events per hour is defined as mild apnea; 16 to 30, moderate apnea; and severe apnea, more than 30.
5,12
According to anthropometric and physiologic predictors, OSAS is a common disease in the middle-aged population, in general affecting both males and females.
2 Postmenopausal women may have OSAS as frequently as men. Obesity is a known risk factor directly related to OSAS. 13, Obese individuals with OSAS have a higher fat volume and increase in cervical soft tissue structures on the airway, causing a reduction in size and alterations in the function of the respiratory muscles, promoting airflow obstruction.
8-10
The respiratory problems associated with OSAS result from different anatomical and pathophysiological changes, which make it difficult to establish a single treatment that covers all cases. One conventional treatment is the MRA, which generally requires 4 weeks of adaptation to the device followed by 2 to 3 months of stepwise mandibular advancement (titration of the device) to maximize the acceptance of the appliance. A mandibular advancement of 50 to 75% of the maximum voluntary protrusion of the individual has been associated with favorable treatment results.
11-13
The main difficulty is to achieve an adequate mandibular advancement without causing discomfort to the patient during the first night of use.
Inclusion Criteria for Studies

Type of Study
We reviewed published randomized controlled trials with experimental and control group addressing the research question: which factors best correlate with treatment success in patients with obstructive sleep apnea syndrome treated with a mandibular repositioning appliance.
Type of Participants
Studies with participants of both genders, over 16 years of age, with a diagnosis of OSAS, and with more than five apneas/hypopneas per hour of sleep were included.
Type of Intervention
The treatment group included studies that reported treatment with any MRA for OSAS; the control group included studies that reported OSAS treatments using another intervention (surgical or nonsurgical) or no intervention. 
Search Methods
Data Extraction
Primary outcomes include AHI. Secondary outcomes included other parameters of PSG, such as quality, architecture, and sleep continuity; nasal/oral airflow; quality and quantity measurement of respiratory effort; saturation of oxyhemoglobin; oxygen desaturation; body position; quality of life; and cognitive function.
Data Analysis
The selection of the studies took place in three phases. First, articles were selected from PubMed, followed by articles from other electronic databases using the search terms mentioned previously. From these and based on the information provided in the title and the abstract, examiners selected the articles to read the entire text. Then, articles in which predictive factors of MRA treatment were possibly discussed were selected. The grading of evidence from selected studies was also performed by the same two independent reviewers according to slight modification of the criteria and classified according to sample size calculation, randomization, clear definition of the inclusion and/or exclusion criteria, follow-up completion (and reasons for withdrawal in each study group were specified), experimental and control group comparable at baseline, presence of blinding, appropriate statistical analysis, and calibration of examiners. 15, 16 The total score was calculated for each study and the results regarding quality were evaluated and considered, as follows: <7 points, high risk of bias (not reviewed); 7 to 10 points, moderate risk of bias; and >10 points, low risk of bias. Moreover, the strengths and weakness of all the included studies were assessed according to Cochrane Reviewers' Handbook.
5
Discussion
Description of Studies
Initially, 69 articles were selected from PubMed and 2 from Cochrane Library. Of these, 30 were excluded based on the title and 12 were excluded based on the abstract, with 29 retrieved for complete reading. Then, 7 articles were excluded because of the methodological quality of the studies and 6 because the study did not address the research question. A total of 13 articles and 1 systematic review were considered eligible for further review and inclusion in this study. The article selection process is charted in ►Fig. 1.
There was no disagreement about study inclusion between reviewers. The most important limitation of this study is the heterogeneity of the articles, due to differences in disease severity and how the authors defined treatment success. ►Table 1 lists the studies reviewed by the authors in relation anthropometric and physiologic factors.
16-21
No randomized controlled trials addressing cephalometric and anatomical factors were found to be included in this Mild to moderate disease severity. In patients with mild to moderate OSAS, authors found that CPAP and MRA effectively treated sleep-disorder breathing and sleepiness; however, the expected response in neurobehavioral function was incomplete. This may be due to MRA having a lesser therapeutic effect and CPAP being poorly tolerated (used less in this patient group).
Engelman et al 18 Mixed disease severity. Objective sleepiness, cognitive performance, and preference for treatment were not different. In patients treated with CPAP versus MRA experiencing a mild form of the syndrome (AHI < 15, n ¼ 18), symptoms, treatment efficacy satisfaction, and subjective sleepiness were better with CPAP than MRA. These results do not support the MRA as first-line treatment for patients with OSAS.
Hoekema et al 19
Mixed disease severity. MRA therapy was less effective in individuals with severe disease (AHI > 30). Because these patients could be at particular risk for cardiovascular disease, primary MRA therapy appears to be supported only for those with nonsevere apnea.
Metha et al 20
Mixed disease severity. MRA used in this study was well tolerated, at least in the short term, and was associated with substantial subjective and objective improvements in a significant proportion of patients. These results support the use of MRA even in some of the patients with more severe forms of OSAS.
Tan et al 21 Mild to moderate disease severity. (1) MRA may be a suitable alternative to nasal CPAP in patients with mild to moderate OSAS; (2) larger studies on the long-term efficacy of the MRA will be required before MRA can be offered as definitive alternative to nasal CPAP; (3) MRAs were well tolerated and preferred by the majority of patients.
Wilhemson et al 22 Mild to moderate disease severity. Findings suggest that the MRA is useful in the treatment of mild to moderate OSAS.
Abbreviations: AHI, apnea-hypopnea index; CPAP, continuous positive airway pressure therapy; MRA, mandibular repositioning appliance; OSAS, obstructive sleep apnea syndrome. 
Summary of Evidence
MRAs are widely prescribed for the treatment of OSAS both as primary therapy and as an alternative for patients who are unable to tolerate continuous positive airway pressure therapy. Although significant progress has been made in demonstrating the efficacy of MRA for OSAS, numerous methodologic weaknesses in published studies bring uncertainty about the role of this therapy in the routine management of OSAS. Until the mid to late 1990s, the majority of studies on the use of MRA in OSAS were short term, not controlled, small, and retrospective. More recently, the quality of MRA clinical research has become more rigorous.
20
This review identified 13 randomized controlled trials with low or moderate methodologic quality involving participants with varied degrees of OSAS severity and 1 systematic review. However, the evidence to support the ability to predict treatment outcome and hence to preselect suitable candidates for this treatment option still remains in its early stages of development.
Predictors of Response to the MRA
The reviewed studies identified a range of anthropomorphic, physiologic, and PSG variables associated with better treatment outcome. Practice parameters developed by the This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
American Academy of Sleep Medicine recommend the use of MRAs only for those patients with mild OSAS or those who refuse or cannot tolerate continuous positive airway pressure therapy. Several studies support this conclusion. However, there is growing evidence supporting an expansion of use of MRAs in more severe forms of OSA, provided that patients are followed cautiously and objective verification of outcome is monitored. The pretreatment AHI, which reflects disease severity, has been suggested as a possible indicator of treatment effect in OSAS patients, with generally higher index levels suggesting treatment failure. 20, [30] [31] [32] [33] The positive effect of the dental appliance was also independent of whether the predominant obstruction was in the oropharynx, the hypopharynx, or both. Some evidence indicates that moderate to severe OSAS is closely associated with obesity and indicates that the dental appliance is an effective treatment in obese patients.
29,34
Further work is required to determine the most effective design and vertical dimension opening of MRAs as a predictor of treatment success. The majority of the studies have compared devices of different design. 20, 25, 35, 36 The differences in results may be due to differences in the study design, in the way the MRA was titrated, in the baseline characteristics of the studies participants (e.g., the severity of OSA), in the primary outcome variable chosen, or in the specifics of the appliances and devices used. At least in part this uncertainty is related to how treatment success is defined and what factors can be clinically used as predictors of success.
37-41
The results of this review justify well-designed, largescale, randomized controlled trials to assess the effectiveness of MRA treatment.
Conclusion
This review of the published literature suggests that it is unclear which factors can be used with confidence to select patients suitable for OSAS treatment with MRAs. We are only able to make some assertions:
• Implications of this review for clinical practice: In the absence of clear predictors of MRA success, it would seem critical to monitor all subjects who have had an MRA fitted with a further overnight sleep study to make sure that the appliance provides satisfactory control of the disease.
• Implication of this review for research: Although significant progress has been reported in proving the efficacy of MRA for OSAS, the ability to predict treatment outcome and hence to preselect suitable candidates for this treatment still remains in its early stages. The review of these clinical trials suggests that there is need to conduct more randomized control trials comparing MRA with not only other treatments as controls but also placebo controls. Numerous methodologic weaknesses in published studies bring uncertainty about the role of this therapy in the routine management of OSAS.
